MINI FUTURE LONG - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 15:58:26 2024-06-14 EDT | ||
| 20.17 EUR | +0.90% |
|
| Current month | +13.83% | ||
| 1 month | +31.32% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 20.17 | +0.90% |
| 24-06-13 | 19.99 | +2.46% |
| 24-06-12 | 19.51 | -3.51% |
| 24-06-11 | 20.22 | -0.79% |
| 24-06-10 | 20.38 | -0.05% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 03:58 pm
More quotesStatic data
| Product type | Warrant Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MD5FPA |
| ISIN | DE000MD5FPA6 |
| Date issued | 2022-06-21 |
| Strike | 265 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.97 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.42 € |
|---|---|
| Lowest since issue | 4.26 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Certificates
- Certificat
